Compositions and methods are disclosed for treating anxiety or stress in an animal, for reducing elevated levels of 4-EPS in an animal with elevated 4-EPS levels, for preventing elevated levels of 4-EPS in an animal and for promoting growth of beneficial microbes in an animal's microbiome and inhibiting growth of non-beneficial microbes. The methods comprise administering to the animal an effective amount of soy protein and vitamin C. Compositions are disclosed which comprise amounts of soy protein and vitamin C effective for use in the methods.

The present embodiments are directed to compositions comprising quillaja extract and at least one active ingredient such as nutritional supplement, dietary ingredient, medicine, and food additive, and methods for preparations and use thereof.

Provided is a solid homogeneous composition comprising at least one cannabinoid and a carrier having at least two of: (i) a total cannabinoid concentration greater than 5%; (ii) being in comminuted particle form, wherein at least 70 wt % of said particles are of size greater than 0.3 millimeter and less than 4.2 millimeters; (iii) comprising less than 20 wt % water; (iv) said carrier comprising cellulose; (v) said carrier comprises less than 50% by weight cannabis or hemp non-cannabinoid plant material, wherein said composition is suitable for providing cannabinoid via inhalation. Further provided are products comprising the composition, methods of use and methods of preparation thereof.

The present invention contemplates a high dose finished pharmaceutical dosage form comprising colestipol hydrochloride in its commercially available form (i.e., beads) without the need for further milling. A manufacturing process used to manufacture the instant high dose finished pharmaceutical dosage form comprising colestipol hydrochloride, which monitors moisture content throughout the granulation process, is also disclosed herein.

The present invention relates to the use of surface-reacted calcium carbonate as stabilizing agent for a probiotic composition, wherein the surface-reacted calcium carbonate is a reaction product of natural ground calcium carbonate or precipitated calcium carbonate with carbon dioxide and one or more H.sub.3O.sup.+ ion donors, wherein the carbon dioxide is formed in situ by the H.sub.3O.sup.+ ion donors treatment and/or is supplied from an external source.

Long-lasting, resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of Parkinson's disease. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period. The implant may have only nicotinamide adenine dinucleotide (NADH), but is preferably formed of NADH particles homogeneously dispersed in a bioerodible and bioabsorbable polymer matrix. Implants can have any size, shape or structure that facilitates their manufacture and subcutaneous insertion, however, to obtain a more constant and uniform release of the active ingredient, it is necessary to use geometric shapes that maintain their surface area over time. The implant may have a polymeric coating membrane and the polymer used for the coating must be bioabsorbable and allow the passage of the active substance.

GHB drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least GHB drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the GHB drug entrapped therein for at least about 3 hours.

Provided is a dosage form comprising magnesium threonate having enhanced efficacy. Also provided is a pharmacokinetic profile of magnesium threonate having enhanced efficacy. The dosage forms and pharmacokinetic profile of magnesium threonate are used to treat a variety of diseases, disorders, syndromes and/or conditions.

Disclosed is a method for production of honey powder that includes the process steps of mixture of at least an auxiliary encapsulation agent selected from a group consisting of water soluble gum, maltodextrin, starch, gelatine, sodium caseinate pectin or mixture of them, measuring viscosity of mixture, adding distilled water to mixture until a viscosity value of 15-20 mPa.s is achieved, applying a homogenization process, bringing a temperature of mixture to 45° C., and obtaining honey powder by drying at a spray drier.

The present disclosure relates to field of Pharmaceutical Chemistry. The present disclosure particularly relates to Compound of Formula-I and process of preparation of the said Compound of Formula-I. The present disclosure further relates to Composition comprising the Compound of Formula-I and active ingredients, such as active pharmaceutical ingredient, dietary ingredients and cosmetic ingredients. The said composition possesses improved solubility and improved bioavailability for the active ingredients such as active pharmaceutical ingredient, dietary ingredients and cosmetic ingredients.

##STR00001##